BI 811283

Drug Profile

BI 811283

Latest Information Update: 23 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 31 Aug 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Germany (IV)
  • 31 Aug 2015 Discontinued - Phase-I/II for Acute myeloid leukaemia (Combination therapy) in Germany (IV)
  • 25 Nov 2011 Boehringer Ingelheim completes enrolment in its Phase-I/IIa trial for Acute myeloid leukaemia in Germany (NCT00632749)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top